Search results
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks· 24 hours agoFree Report) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 1.9% over this ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 17 hours agoBarclays‘s target price would suggest a potential upside of 14.94% from the company’s previous close. Several other equities research analysts have also recently commented on ABBV. BMO Capital ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 1 day agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. < ...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 5 days agoThe company even upped its full-year profit outlook. But AbbVie stock fell all the same, closing...
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 3 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 6 days agoAbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the...
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoAbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript April 26, 2024 AbbVie Inc. beats earnings...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 4 days agoThe Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 2 days agoA number of other analysts have also recently weighed in on the company. Truist Financial raised their price objective on AbbVie from $180.00 to $195.00 and gave the
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 5 days agoAbbVie is "firing on all cylinders," an analyst said Friday after the pharma giant beat Wall...
